News

Article

Janssen Defends Remicade Patents in New Lawsuit

Janssen filed a lawsuit in a US District Court in New Jersey against Samsung Bioepis, claiming the company’s new biosimilar infringed on its Remicade patents.

On May 17, 2017, Janssen, a subsidiary of Johnson & Johnson (J&J), filed a lawsuit in a district court in New Jersey against Samsung Bioepis, alleging the company’s recently approved infliximab biosimilar infringes on Janssen’s patents for Remicade (infliximab). The lawsuit seeks to halt the commercial marketing of Samsung’s biosimilar Renflexis (infliximab-abda) in the United States.

Renflexis is the second FDA-approved biosimilar for Remicade and the first Samsung Bioepis product approved for marketing in the US. Samsung told Reuters it believes the lawsuit is an attempt by Janssen to impede its Remicade biosimilar’s entry into the US market.

"We are confident we do not infringe Janssen's patents," Samsung Bioepis told Reuters. "We will take all necessary measures against Janssen's attempts to violate patient rights and deny patient access to effective, lower-cost treatment options."

Remicade is a blockbuster treatment for J&J and accounted for approximately 9.7% of the company’s 2016 revenue. J&J has said that it plans to “vigorously defend” its patents for the treatment, which is the company’s highest selling US product, accounting for nearly $5 billion in sales.

Source: United States District Court of New Jersey, Reuters 

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Related Videos
A global supply chain map, visualizing the complex network of transportation routes and distribution centers | Image Credit: © venusvi - stock.adobe.com
Shortcut from point A to point B | Image Credit: © Olivier Le Moal - stock.adobe.com
Behind the Headlines, Episode 21: Waters-BD Merger, Merck’s $10B Bet, and Biotech’s Investment Frontiers
Wooden blocks spelling TARIFFS are placed on a map of North America, specifically over the United States and Mexico | Image Credit: © Rokas - stock.adobe.com
Jason Waite, International Trade Expert, Alston & Bird
Simona Guidi, Associate Director, ProPharma
Tore Bergsteiner
Behind the Headlines, Episode 20: CAR-T Milestones, Abbvie and Eli Lilly M&A Moves, and More
Related Content